NasdaqGS - Delayed Quote • USD
AlloVir, Inc. (ALVR)
At close: 4:00 PM EDT
After hours: 4:06 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 4 | 3 |
| Avg. Estimate | -0.16 | -0.09 | -0.42 | -0.3 |
| Low Estimate | -0.19 | -0.14 | -0.58 | -0.5 |
| High Estimate | -0.13 | -0.03 | -0.24 | 0 |
| Year Ago EPS | -0.44 | -0.48 | -1.65 | -0.42 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 4 | 3 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.46 | -0.45 | -0.42 | -0.43 |
| EPS Actual | -0.44 | -0.48 | -0.39 | -0.36 |
| Difference | 0.02 | -0.03 | 0.03 | 0.07 |
| Surprise % | 4.30% | -6.70% | 7.10% | 16.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.16 | -0.09 | -0.42 | -0.3 |
| 7 Days Ago | -0.14 | -0.08 | -0.44 | -0.3 |
| 30 Days Ago | -0.16 | -0.11 | -0.47 | -0.39 |
| 60 Days Ago | -0.18 | -0.1 | -0.45 | -0.54 |
| 90 Days Ago | -0.18 | -0.1 | -0.45 | -0.54 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | 1 | -- |
| Up Last 30 Days | 1 | -- | 1 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ALVR | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 63.60% | -- | -- | 1.60% |
| Next Qtr. | 81.30% | -- | -- | 10.50% |
| Current Year | 74.50% | -- | -- | 5.20% |
| Next Year | 28.60% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Downgrade | B of A Securities: Buy to Underperform | 12/26/2023 |
| Downgrade | Leerink Partners: Outperform to Market Perform | 12/22/2023 |
| Downgrade | Piper Sandler: Overweight to Neutral | 12/22/2023 |
| Downgrade | JP Morgan: Overweight to Underweight | 12/22/2023 |
| Initiated | B of A Securities: Buy | 8/18/2023 |
| Reiterates | Morgan Stanley: Overweight to Overweight | 8/7/2023 |
Related Tickers
RPHM Reneo Pharmaceuticals, Inc.
1.7400
-1.14%
ANTX AN2 Therapeutics, Inc.
2.4700
+3.78%
DSGN Design Therapeutics, Inc.
3.7000
-1.07%
ACHL Achilles Therapeutics plc
0.7829
-2.14%
CYCN Cyclerion Therapeutics, Inc.
3.5000
+5.58%
AVIR Atea Pharmaceuticals, Inc.
3.7200
+0.54%
SNSE Sensei Biotherapeutics, Inc.
0.9700
+1.04%
ACIU AC Immune SA
2.3600
-0.84%
CNTB Connect Biopharma Holdings Limited
1.5400
+1.32%
BOLT Bolt Biotherapeutics, Inc.
1.1100
-2.63%